|

Toripalimab Injection Clinical Trials

7 actively recruiting trials across 1 location

Also known as: JS001, Toripalimab

Pipeline

Phase 2: 3Phase 3: 2Phase 1/2: 2

Top Sponsors

  • Wan He1
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Shanghai Junshi Bioscience Co., Ltd.1
  • Risen (Suzhou) Pharma Tech Co., Ltd.1
  • Nanjing Leads Biolabs Co.,Ltd1

Indications

  • Cancer7
  • Breast Cancer2
  • PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1
  • Limited-stage Small Cell Lung Cancer (LS-SCLC)1
  • Urothelial Carcinoma1

Other6 trials

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Phase 2
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Phase 1/2
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/2
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
Phase 2

Goodyear, Arizona1 trial

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Banner MD Anderson Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.